Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Saila Kauhanen

Showing results (1-10 of 34) with videos related to

Pageof 4
Sort By:
Endocrine|July 17, 2012
Is there a role for fluorine-18 fluorodeoxyglucose positron emission tomography imaging in medullary thyroid cancer?Saila Kauhanen, Camilla Schalin-Jäntti
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 16, 2008
Premedication with carbidopa masks positive finding of insulinoma and beta-cell hyperplasia in [(18)F]-dihydroxy-phenyl-alanine positron emission tomographySaila Kauhanen, Marko Seppänen, Pirjo Nuutila
Duodecim; Laaketieteellinen Aikakauskirja|October 24, 2012
[Pancreatic adenocarcinoma--a therapeutic challenge]Eija Korkeila, Saila Kauhanen, Miia Mokka
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|November 14, 2009
18F-FDOPA: a multiple-target moleculeHeikki Minn, Saila Kauhanen, Marko Seppänen, et al.
PET Clinics|July 18, 2014
18F-fluorodihydroxyphenylalanine in the diagnosis of neuroendocrine tumorsHeikki Minn, Jukka Kemppainen, Saila Kauhanen, et al.
Cancer Management and Research|September 2, 2024
Outcomes After Multimodality Treatment of Pancreatic Cancer in an Unselected Single-Center CohortEetu Heervä, Vesa Väliaho, Heidi Nurmi, et al.
Oncology|October 29, 2020
TKTL1 as a Prognostic Marker in Pancreatic Ductal Adenocarcinoma and Its Correlation with FDG-PET-CTKaisa Ahopelto, Kapo Saukkonen, Jaana Hagström, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 27, 2009
Decreased blood flow with increased metabolic activity: a novel sign of pancreatic tumor aggressivenessGaber Komar, Saila Kauhanen, Kaisa Liukko, et al.
EJNMMI Research|December 14, 2016
Low kidney uptake of GLP-1R-targeting, beta cell-specific PET tracer, <sup>18</sup>F-labeled [Nle<sup>14</sup>,Lys<sup>40</sup>]exendin-4 analog, shows promise for clinical imagingKirsi Mikkola, Cheng-Bin Yim, Paula Lehtiniemi, et al.
Endocrine|June 2, 2025
Chromogranin a and pancreatic polypeptide are not suitable for the screening of pancreatic neuroendocrine tumors in MEN1 - a long-term follow-up studyIiro Kostiainen, Susanna Majala, Jukka Schildt, et al.
Pageof 4

Showing results (1-10 of 34) with videos related to

Sort By:
Pageof 4
Endocrine|July 17, 2012
Is there a role for fluorine-18 fluorodeoxyglucose positron emission tomography imaging in medullary thyroid cancer?Saila Kauhanen, Camilla Schalin-Jäntti
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 16, 2008
Premedication with carbidopa masks positive finding of insulinoma and beta-cell hyperplasia in [(18)F]-dihydroxy-phenyl-alanine positron emission tomographySaila Kauhanen, Marko Seppänen, Pirjo Nuutila
Duodecim; Laaketieteellinen Aikakauskirja|October 24, 2012
[Pancreatic adenocarcinoma--a therapeutic challenge]Eija Korkeila, Saila Kauhanen, Miia Mokka
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|November 14, 2009
18F-FDOPA: a multiple-target moleculeHeikki Minn, Saila Kauhanen, Marko Seppänen, et al.
PET Clinics|July 18, 2014
18F-fluorodihydroxyphenylalanine in the diagnosis of neuroendocrine tumorsHeikki Minn, Jukka Kemppainen, Saila Kauhanen, et al.
Cancer Management and Research|September 2, 2024
Outcomes After Multimodality Treatment of Pancreatic Cancer in an Unselected Single-Center CohortEetu Heervä, Vesa Väliaho, Heidi Nurmi, et al.
Oncology|October 29, 2020
TKTL1 as a Prognostic Marker in Pancreatic Ductal Adenocarcinoma and Its Correlation with FDG-PET-CTKaisa Ahopelto, Kapo Saukkonen, Jaana Hagström, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 27, 2009
Decreased blood flow with increased metabolic activity: a novel sign of pancreatic tumor aggressivenessGaber Komar, Saila Kauhanen, Kaisa Liukko, et al.
EJNMMI Research|December 14, 2016
Low kidney uptake of GLP-1R-targeting, beta cell-specific PET tracer, <sup>18</sup>F-labeled [Nle<sup>14</sup>,Lys<sup>40</sup>]exendin-4 analog, shows promise for clinical imagingKirsi Mikkola, Cheng-Bin Yim, Paula Lehtiniemi, et al.
Endocrine|June 2, 2025
Chromogranin a and pancreatic polypeptide are not suitable for the screening of pancreatic neuroendocrine tumors in MEN1 - a long-term follow-up studyIiro Kostiainen, Susanna Majala, Jukka Schildt, et al.
Pageof 4